NZ783377A - Pegylated novel molecules for agonising tlr2 - Google Patents

Pegylated novel molecules for agonising tlr2

Info

Publication number
NZ783377A
NZ783377A NZ783377A NZ78337720A NZ783377A NZ 783377 A NZ783377 A NZ 783377A NZ 783377 A NZ783377 A NZ 783377A NZ 78337720 A NZ78337720 A NZ 78337720A NZ 783377 A NZ783377 A NZ 783377A
Authority
NZ
New Zealand
Prior art keywords
tlr2
agonising
pegylated
novel molecules
compositions
Prior art date
Application number
NZ783377A
Other languages
English (en)
Inventor
Ian Holmes
Weiguang Zeng
David Jackson
Christophe Demaison
Grant Mclachlan
Original Assignee
Ena Respiratory Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019902231A external-priority patent/AU2019902231A0/en
Application filed by Ena Respiratory Pty Ltd filed Critical Ena Respiratory Pty Ltd
Publication of NZ783377A publication Critical patent/NZ783377A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
    • C07C321/12—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms
    • C07C321/14—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/14—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
    • C07C319/20—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides by reactions not involving the formation of sulfide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/334—Polymers modified by chemical after-treatment with organic compounds containing sulfur
    • C08G65/3348—Polymers modified by chemical after-treatment with organic compounds containing sulfur containing nitrogen in addition to sulfur

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
NZ783377A 2019-06-26 2020-06-26 Pegylated novel molecules for agonising tlr2 NZ783377A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2019902231A AU2019902231A0 (en) 2019-06-26 Novel molecules
AU2019904862A AU2019904862A0 (en) 2019-12-20 Novel molecules (2)
PCT/AU2020/050660 WO2020257870A1 (en) 2019-06-26 2020-06-26 Novel molecules

Publications (1)

Publication Number Publication Date
NZ783377A true NZ783377A (en) 2026-03-27

Family

ID=74059610

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ783377A NZ783377A (en) 2019-06-26 2020-06-26 Pegylated novel molecules for agonising tlr2

Country Status (12)

Country Link
US (2) US20220388950A1 (https=)
EP (1) EP3990428A4 (https=)
JP (2) JP2022539091A (https=)
KR (1) KR20220050873A (https=)
CN (2) CN121045535A (https=)
AU (1) AU2020302839B2 (https=)
BR (1) BR112021025630A8 (https=)
CA (1) CA3142501A1 (https=)
IL (1) IL289266B1 (https=)
MX (1) MX2021015961A (https=)
NZ (1) NZ783377A (https=)
WO (1) WO2020257870A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2618842B1 (en) 2010-09-22 2019-04-24 Ena Therapeutics Pty Ltd Novel immunostimulatory method
AU2018391325B2 (en) 2017-12-21 2024-07-11 Axelia Oncology Pty Ltd Optimised compounds
MX2021015961A (es) 2019-06-26 2022-03-22 Ena Respiratory Pty Ltd Moleculas novedosas.
WO2021237291A1 (en) * 2020-05-26 2021-12-02 Axelia Oncology Pty Ltd Treatment of coronavirus
JP7744936B2 (ja) 2020-06-26 2025-09-26 イーナ レスパラトリー ピーティーワイ リミテッド 分岐脂質化合物
WO2023028661A1 (en) * 2021-09-02 2023-03-09 Ena Respiratory Pty Ltd Formulation

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ520976A (en) 1999-11-19 2005-01-28 Csl Ltd Vaccine compositions
HU230847B1 (en) 2000-05-19 2018-08-28 Corixa Corp Prophylactic and therapeutic treatment of infectious and other diseases with mono and disaccharide-based compounds
EP1382352A1 (de) 2002-07-19 2004-01-21 GBF Gesellschaft für Biotechnologische Forschung mbH Bisacyloxypropylcystein-Konjugate und deren Verwendung
AU2003250586B2 (en) 2002-08-12 2010-09-23 The Council Of The Queensland Institute Of Medical Research Novel immunogenic lipopeptides comprising T-helper and B-cell epitopes
BR0313101A (pt) 2002-08-12 2005-06-28 Queensland Inst Med Res Novos lipopeptìdeos imunogênicos que compreendem epitopos de linfócitos t-helper e linfócitos t citotóxicos (ctl), e métodos para sua produção e uso
EP1550458A1 (en) 2003-12-23 2005-07-06 Vectron Therapeutics AG Synergistic liposomal adjuvants
US20060002941A1 (en) 2004-01-23 2006-01-05 Vievax Corp. Compositions comprising immune response altering agents and methods of use
WO2005079419A2 (en) 2004-02-17 2005-09-01 The Regents Of The University Of California Methods of treating immunopathological disorders
GB0405634D0 (en) 2004-03-12 2004-04-21 Univ Southampton Anti-virus therapy for respiratory diseases
GB0411411D0 (en) 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
EP2460533A3 (en) 2004-10-18 2014-01-08 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
EP1666056A1 (en) 2004-12-06 2006-06-07 Bestewil Holding B.V. Cancer vaccine vesicles
US8420102B2 (en) 2006-03-07 2013-04-16 Vaxinnate Corporation Compositions that include hemagglutinin
NZ556004A (en) 2004-12-21 2010-05-28 Vaxinnate Corp Compositions of influenza viral proteins comprising at least one flagellin and at least one influenza M2 protein
CN101151280A (zh) 2005-02-08 2008-03-26 昆士兰医学研究学院委员会 免疫原性分子
US7560436B2 (en) 2005-02-22 2009-07-14 The Regents Of The University Of California Methods of treating gastrointestinal inflammation
EP1787660A1 (en) * 2005-11-22 2007-05-23 GBF Gesellschaft für Biotechnologische Forschung mbH New adjuvants on the basis of bisacyloxypropylcysteine conjugates and their uses in pharmaceutical compositions
WO2008085549A2 (en) 2006-07-28 2008-07-17 Board Of Regents Of The University Of Texas System Compositions and methods for stimulation of lung innate immunity
AU2014202674B2 (en) * 2007-05-04 2014-08-14 Marina Biotech, Inc. Amino acid lipids and uses thereof
AU2008310313C1 (en) 2007-10-09 2015-02-12 Ena Respiratory Pty Ltd A method of transfection and compositions therefor
WO2009137103A2 (en) 2008-05-09 2009-11-12 Ourth Donald D Anti-cancer/anti-viral compounds and methods of use
US8728465B2 (en) 2008-06-17 2014-05-20 Cedars-Sinai Medical Center Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors
WO2010028246A2 (en) 2008-09-05 2010-03-11 Id Biomedical Corporation Of Quebec Novel compositions and adjuvants
KR20110117705A (ko) 2009-02-11 2011-10-27 더 리전트 오브 더 유니버시티 오브 캘리포니아 톨-유사 수용체 조정제 및 질병의 치료
CN103800906B (zh) 2009-03-25 2017-09-22 德克萨斯大学系统董事会 用于刺激哺乳动物对病原体的先天免疫抵抗力的组合物
JP2012523379A (ja) 2009-04-09 2012-10-04 ザ ユニバーシティー オブ メルボルン 免疫原性組成物およびその使用
GB0907989D0 (en) 2009-05-08 2009-06-24 Hybrid Systems Ltd Multivalent adjuvant display
EP2338521A1 (en) 2009-12-28 2011-06-29 Helmholtz-Zentrum für Infektionsforschung GmbH Lipopeptide- and lipoprotein-conjugates and its use
EA031379B1 (ru) * 2010-03-23 2018-12-28 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
EP2618842B1 (en) 2010-09-22 2019-04-24 Ena Therapeutics Pty Ltd Novel immunostimulatory method
CN113876945A (zh) * 2011-10-06 2022-01-04 免疫疫苗技术有限公司 包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用
EP3604271A1 (en) 2013-06-28 2020-02-05 Auckland Uniservices Limited Peptides for amino acid and peptide conjugates and conjugation process
US20170274068A1 (en) 2014-09-12 2017-09-28 The University Of Melbourne Immunological reagent
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
JP2016216593A (ja) 2015-05-19 2016-12-22 株式会社リコー 反応材、熱交換器及びケミカルヒートポンプ
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
TW201735952A (zh) * 2016-02-26 2017-10-16 瑪格蕾特 安 布萊博 胺基酸及肽共軛物以及共軛過程
CN110461351B (zh) * 2017-03-31 2024-03-26 艾娜呼吸私人有限公司 用tlr2激动剂治疗呼吸道感染
NL2018803B1 (en) * 2017-04-27 2018-11-05 Academisch Ziekenhuis Leiden Handelend Onder De Naam Leids Univ Medisch Centrum/ H O D N Lumc Adjuvant compounds
EP3676250A4 (en) * 2017-08-30 2021-05-26 Auckland Uniservices Limited PEPTIDE CONJUGATES, CONJUGATION METHODS AND USES THEREOF
AU2018391325B2 (en) 2017-12-21 2024-07-11 Axelia Oncology Pty Ltd Optimised compounds
WO2019119069A1 (en) 2017-12-21 2019-06-27 Ena Therapeutics Pty Ltd Administration of a tlr2 agonist for the treatment or prevention of a respiratory condition associated with an infectious agent
MX2021015961A (es) * 2019-06-26 2022-03-22 Ena Respiratory Pty Ltd Moleculas novedosas.
US20220347146A1 (en) 2019-09-04 2022-11-03 Axelia Oncology Pty Ltd Cancer treatment
AU2020340468A1 (en) 2019-09-04 2022-03-24 Axelia Oncology Pty Ltd Cancer immunotherapy
WO2021237291A1 (en) 2020-05-26 2021-12-02 Axelia Oncology Pty Ltd Treatment of coronavirus

Also Published As

Publication number Publication date
BR112021025630A2 (pt) 2022-02-15
IL289266B1 (en) 2026-03-01
BR112021025630A8 (pt) 2023-04-11
EP3990428A4 (en) 2023-07-19
JP2022539091A (ja) 2022-09-07
KR20220050873A (ko) 2022-04-25
US12017979B2 (en) 2024-06-25
US20220388950A1 (en) 2022-12-08
CN114174260A (zh) 2022-03-11
CA3142501A1 (en) 2020-12-30
JP2025108536A (ja) 2025-07-23
EP3990428A1 (en) 2022-05-04
AU2020302839B2 (en) 2025-08-14
MX2021015961A (es) 2022-03-22
IL289266A (en) 2022-02-01
AU2020302839A1 (en) 2022-01-20
US20230257345A1 (en) 2023-08-17
WO2020257870A1 (en) 2020-12-30
CN114174260B (zh) 2025-09-05
CN121045535A (zh) 2025-12-02

Similar Documents

Publication Publication Date Title
NZ783377A (en) Pegylated novel molecules for agonising tlr2
PH12020500500A1 (en) Pyrazolopyrimidinone compounds and uses thereof
PH12020550051B1 (en) Glp-1 compositions and uses thereof
EP4219713A3 (en) Products and compositions
MX2023013435A (es) Composiciones y metodos para expresar otoferlina.
NZ759766A (en) Use of lactic acid bacteria to treat or prevent at least one of postnatal depression and postnatal anxiety
MX2018001075A (es) Agentes terapeuticos y profilacticos antibacterianos.
CL2018002826A1 (es) Proteínas f de prefusión del virus respiratorio sincicial (vrs) solubles y estabilizadas
WO2017004591A3 (en) Stabilized anti-microbial peptides
MX2020014031A (es) Proteinas heterodimericas y usos de las mismas.
SA523440384B1 (ar) مركبات الفوسفوليبيدات واستخداماتها
ZA202002093B (en) Antibacterial compounds
MX2021010458A (es) Uso de virus oncoliticos para el tratamiento del cancer.
WO2018226992A8 (en) Tau aggregation inhibitors
MX2020006191A (es) Bacteriocinas terapeuticas.
MY189342A (en) Treatment and prevention of the common cold using povidone-iodine
PH12020551618A1 (en) Erenumab compositions and uses thereof
GB2568440A (en) Modified factor H binding protein
MY191930A (en) Microbial lysozyme for use in the treatment of irritable bowel syndrome or inflammatory bowel disease
MX2020012543A (es) Diltiazem para usarse en el tratamiento de infecciones microbianas.
PH12020551331A1 (en) Treatment and prevention of pre-eclampsia
PH12017500816A1 (en) Long acting pharmaceutical compositions for hepatitis c
PH12017500820A1 (en) Combination long acting compositions and methods for hepatitis c
MY184269A (en) Broad-spectrum anti-influenza virus therapeutic peptides
BR112021026193A2 (pt) Composições e métodos para tratar ou prevenir infecções oculares com filociclovir

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: ENA RESPIRATORY PTY LTD, AU

Effective date: 20230314